Business
GenSight Biologics Reports Interim Financial Results for the First Half of 2025
PARIS, September 29, 2025--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial results for the first half of 2025.
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/0bf147d38046cfa9fea900841c103b83"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vHQFpazc959fLVt5eKb3gw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0bf147d38046cfa9fea900841c103b83","width":480,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Optimized cash management results in 8.3% reduction in operating cash outflow compared to the same period in 2024","length":113,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash runway extended to late Q4 2025 following post-closing financing","length":69,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Manufacturing process transfer to Catalent, Inc., on track","length":58,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Protocol for the dose-ranging study submitted to the ANSM in mid-August","length":71,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":311,"olType":false},{"type":"text","content":"PARIS, September 29, 2025--(BUSINESS WIRE)--Regulatory News:","length":60,"tagName":"p"},{"type":"text","content":"GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial results for the first half of 2025.","length":313,"tagName":"p"},{"type":"text","content":"The 2025 half-year financial statements were subject to a limited review by the Company’s statutory auditors and approved by the Board of Directors on September 26, 2025. The full interim financial report is available on the Company’s website in the Investors section.","length":268,"tagName":"p"},{"type":"text","content":""We have rigorously maintained financial discipline in the first half of 2025, achieving an 8% reduction in cash outflow compared to the prior year period through optimized cash management. The €3.7 million financing we completed last week has extended our cash runway, providing us with sufficient funds until the expected decision of th...